The Central Drugs Standard Control Organization (CDSCO) has granted approval to Novo Nordisk’s blockbuster drug, Ozempic (Semaglutide injection), for use in India. The approval, announced on September 26, allows Ozempic to be prescribed for Type 2 Diabetes as an adjunct to diet and exercise.

Delivered as an injectable solution, Ozempic (0.25mg, 0.5mg and 1mg) is a GLP-1 receptor agonist that improves glycaemic control. Clinical studies have also explored its effects on cardiovascular and kidney outcomes, and the therapy can be combined with other antidiabetic medications for comprehensive management, the drug regulator noted. Advertisement

Ozempic, marketed by Novo Nordisk in India, is primarily indicated for the treatment of type 2 diabetes. While it can lead to moderate weight loss a

See Full Page